Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports. Allakos Price Performance NASDAQ ALLK ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

National Bank Financial reduced their FY2024 earnings per share estimates for shares of Loblaw Companies in a report released on Sunday, January 26th. National Bank Financial analyst V. Shreedhar now ...